Carfilzomib, Daratumumab, Lenalidomide and Dexamethasone as First Line Treatment in Multiple Myeloma
Status:
Withdrawn
Trial end date:
2025-02-28
Target enrollment:
Participant gender:
Summary
Carfilzomib in combination with lenalidomide, daratumumab and dexamethasone (KRDd) can induce
profound clinical responses. The investigators want to observe the effectiveness of the
quadruple therapy of carfilzomib, lenalidomide, daratumumab and dexamethasone on patients
receiving 8 cycles of KRDd with autologous stem cell transplantation versus patients with 8
cycles of KRDd without autologous stem cell transplantation.